Joan M Neuner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7196301/publications.pdf

Version: 2024-02-01

		304602	197736
80	2,595	22	49
papers	citations	h-index	g-index
82	82	82	3186
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Feasibility of a pharmacist-led symptom monitoring and management intervention to improve breast cancer endocrine therapy adherence. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1321-1328.e3.	0.7	3
2	Aromatase Inhibitor Symptom Management Practices: A Retrospective Study. Clinical Breast Cancer, 2021, 21, e38-e47.	1.1	4
3	A dependent Dirichlet process model for survival data with competing risks. Lifetime Data Analysis, 2021, 27, 156-176.	0.4	1
4	The Use and Concurrent Use of Side Effect Controlling Medications Among Women on Aromatase Inhibitors. Journal of Women's Health, 2021, 30, 131-136.	1.5	3
5	Differences in length of stay by teaching team status in an academic medical center in the Midwestern United States. Hospital Practice (1995), 2021, 49, 119-126.	0.5	3
6	Patient-Physician Concordance for Quantitative Formats and Treatment Options and the Relationship with State Anxiety. Journal of Cancer Education, $2021, 1.$	0.6	0
7	The Role of Physician Professional Networks in Physicians' Receipt of Pharmaceutical and Medical Device Industries' Payments. Journal of General Internal Medicine, 2021, 36, 1858-1866.	1.3	5
8	Pharmacy deserts and patients with breast cancer receipt of influenza vaccines. Journal of the American Pharmacists Association: JAPhA, 2021, 61, e25-e31.	0.7	6
9	Neighborhood Characteristics and Cancer Survivorship: An Overview of the Current Literature on Neighborhood Landscapes and Cancer Care. International Journal of Environmental Research and Public Health, 2021, 18, 7192.	1.2	6
10	An adapted two-step floating catchment area method accounting for urban–rural differences in spatial access to pharmacies. Journal of Pharmaceutical Health Services Research, 2021, 12, 69-77.	0.3	6
11	Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 765-768.	3.0	5
12	Results and Lessons of a Pilot Study of Cascade Screening for Familial Hypercholesterolemia in US Primary Care Practices. Journal of General Internal Medicine, 2020, 35, 351-353.	1.3	9
13	Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence. Clinical Breast Cancer, 2020, 20, e261-e280.	1.1	1
14	Newâ€onset persistent opioid use following breast cancer treatment in older adult women. Cancer, 2020, 126, 814-822.	2.0	14
15	The impact of patient-generated contextual data on communication in clinical practice: A qualitative assessment of patient and clinician perspectives. Patient Education and Counseling, 2020, 103, 734-740.	1.0	17
16	Response to Strassels and Durham. Journal of the National Cancer Institute, 2020, 112, 1280-1280.	3.0	0
17	At the intersection of precision medicine and population health: an implementation-effectiveness study of family health history based systematic risk assessment in primary care. BMC Health Services Research, 2020, 20, 1015.	0.9	13
18	Health Insurance Coverage Disruptions and Cancer Care and Outcomes: Systematic Review of Published Research. Journal of the National Cancer Institute, 2020, 112, 671-687.	3.0	61

#	Article	IF	Citations
19	Association of Current Opioid Use With Serious Adverse Events Among Older Adult Survivors of Breast Cancer. JAMA Network Open, 2020, 3, e2016858.	2.8	14
20	Parental Status in Treatment Decision Making among Women with Nonmetastatic Breast Cancer. Medical Decision Making, 2020, 40, 540-544.	1.2	0
21	Reply to E. Gonzalez-Rodriguez et al. Journal of Clinical Oncology, 2020, 38, 1642-1643.	0.8	0
22	The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multiâ€state models to understand the dynamics of adherence. Pharmacoepidemiology and Drug Safety, 2020, 29, 550-557.	0.9	2
23	Implementation, adoption, and utility of family health history risk assessment in diverse care settings: evaluating implementation processes and impact with an implementation framework. Genetics in Medicine, 2019, 21, 331-338.	1.1	24
24	Community Breast Health Education for Immigrants and Refugees: Lessons Learned in Outreach Efforts to Reduce Cancer Disparities. Journal of Cancer Education, 2019, 34, 1092-1096.	0.6	11
25	The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence. Cancer, 2019, 125, 3960-3965.	2.0	5
26	Improving Communication in Breast Cancer Treatment Consultation: Use of a Computer Test of Health Numeracy. Journal of Women's Health, 2019, 28, 1407-1417.	1.5	6
27	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 2916-2946.	0.8	127
28	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline Summary. Journal of Oncology Practice, 2019, 15, 665-669.	2.5	5
29	Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network. Breast Cancer Research and Treatment, 2019, 175, 675-689.	1.1	34
30	Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?. Breast Cancer Research and Treatment, 2019, 176, 205-215.	1.1	11
31	Discussion of preoperative mammography in women undergoing reduction mammaplasty. Breast Journal, 2019, 25, 439-443.	0.4	7
32	Using Group-based Trajectory Models and Propensity Score Weighting to Detect Heterogeneous Treatment Effects. Medical Care, 2019, 57, 85-93.	1.1	11
33	Factors Influencing Prescription Drug Synchronization: The Complex Role of Number of Medications. Journal of Managed Care & Decialty Pharmacy, 2019, 25, 714-718.	0.5	2
34	Effect of Sociodemographic Factors on Uptake of a Patient-Facing Information Technology Family Health History Risk Assessment Platform. Applied Clinical Informatics, 2019, 10, 180-188.	0.8	8
35	Communication and Shared Decision Making in the Breast Cancer Treatment Consultation: A Comparative Analysis of English- and Spanish-Speaking Patients. MDM Policy and Practice, 2019, 4, 238146831988165.	0.5	5
36	Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare populationâ€based study. Clinical Cardiology, 2019, 42, 93-100.	0.7	24

#	Article	lF	CITATIONS
37	Making Sure We Don't Forget the Basics When Using Machine Learning. Journal of the National Cancer Institute, 2019, 111, 529-530.	3.0	2
38	The association of socioeconomic status with receipt of neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2019, 173, 179-188.	1.1	12
39	Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. Journal of Cancer Survivorship, 2018, 12, 268-275.	1.5	9
40	Increasing Mammography Uptake Through Academic-Community Partnerships Targeting Immigrant and Refugee Communities in Milwaukee. Wisconsin Medical Journal, 2018, 117, 55-61.	0.3	4
41	Catalyzing Transdisciplinarity: A Systems Ethnography of Cancer–Obesity Comorbidity and Risk Coincidence. Qualitative Health Research, 2017, 27, 877-892.	1.0	6
42	Geographic Variation of Adjuvant Breast Cancer Therapy Initiation in the United States: Lessons From Medicare Part D. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1509-1517.	2.3	2
43	Tailoring Educational and Behavioral Interventions to Level of Health Literacy: A Systematic Review. MDM Policy and Practice, 2017, 2, 238146831771447.	0.5	28
44	Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. Journal of Clinical Oncology, 2016, 34, 4398-4404.	0.8	37
45	A statewide controlled trial intervention to reduce use of unproven or ineffective breast cancer care. Contemporary Clinical Trials, 2016, 50, 150-156.	0.8	5
46	Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. American Journal of Surgery, 2016, 212, 660-669.	0.9	164
47	No Increase in Fractures after Stopping Hormone Therapy: Results from the Women's Health Initiative. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3270.	1.8	24
48	Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 875-880.	2.3	6
49	Development and Validation of the Spanish Numeracy Understanding in Medicine Instrument. Journal of General Internal Medicine, 2016, 31, 1345-1352.	1.3	11
50	Capsule Commentary on Bell et al., Impact of a Randomized Control Educational Trial to Improve Physician Practice Behaviors Around Screening for Inherited Breast Cancer. Journal of General Internal Medicine, 2016, 31, 326-326.	1.3	0
51	Reexamining the Relationship of Breast Cancer Hospital and Surgical Volume to Mortality. Medical Care, 2015, 53, 1033-1039.	1.1	28
52	The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees. Journal of the National Cancer Institute, 2015, 107, .	3.0	40
53	Determining the Clinical Significance of Monoclonal Gammopathy of Undetermined Significance: A SEER–Medicare Population Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 177-186.e4.	0.2	52
54	Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. SpringerPlus, 2015, 4, 54.	1.2	10

#	Article	IF	Citations
55	Meaningful Use and the Patient Portal. American Journal of Medical Quality, 2015, 30, 105-113.	0.2	60
56	Patient Perceptions of Osteoporosis Treatment Thresholds. Journal of Rheumatology, 2014, 41, 516-522.	1.0	16
57	Dual X-ray Absorptiometry for Diagnosis of Osteoporosis. JAMA - Journal of the American Medical Association, 2014, 312, 1147.	3.8	3
58	Quality of life among a population-based cohort of older patients with breast cancer. Breast, 2014, 23, 609-616.	0.9	34
59	Medicare Part D low-income subsidy and disparities in breast cancer treatment Journal of Clinical Oncology, 2014, 32, 2-2.	0.8	2
60	Medicare Part D low-income subsidy and disparities in breast cancer treatment Journal of Clinical Oncology, 2014, 32, 6534-6534.	0.8	0
61	Baseline bone mineral density testing among breast cancer patients prescribed aromatase inhibitors (Als) Journal of Clinical Oncology, 2013, 31, 6642-6642.	0.8	O
62	Natural History Of Smoldering Monoclonal Gammopathy-Associated Malignancies: A Population-Based Study. Blood, 2013, 122, 5318-5318.	0.6	0
63	The Importance of Physicians' Risk Perception in Osteoporosis Treatment Decision Making. Journal of Clinical Densitometry, 2012, 15, 49-54.	0.5	18
64	The Association of Robotic Surgical Technology and Hospital Prostatectomy volumes. Cancer, 2012, 118, 371-377.	2.0	36
65	Cancer Complications At the Time of Multiple Myeloma Diagnosis and the Impact of Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up: A Population-Based Study. Blood, 2012, 120, 3996-3996.	0.6	1
66	Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporosis International, 2011, 22, 2847-2855.	1.3	33
67	The Relationship of Health Numeracy to Cancer Screening. Journal of Cancer Education, 2011, 26, 103-110.	0.6	19
68	ELDERLY BREAST CANCER SURVIVORS ACCURATELY SELFâ€REPORT KEY TREATMENT INFORMATION. Journal of the American Geriatrics Society, 2010, 58, 410-412.	1.3	9
69	Heightened Attention to Medical Privacy: Challenges for Unbiased Sample Recruitment and a Possible Solution. American Journal of Epidemiology, 2010, 172, 637-644.	1.6	32
70	A Framework for Health Numeracy: How Patients Use Quantitative Skills in Health Care. Journal of Health Communication, 2008, 13, 501-517.	1.2	55
71	A Randomized Study of the Effect of 5-Year and Lifetime Hip Fracture Risk Information on Physician Recommendations for Management of Low Bone Density. Journal of Clinical Densitometry, 2007, 10, 370-375.	0.5	5
72	Long-Term Opioid Contract Use for Chronic Pain Management in Primary Care Practice. A Five Year Experience. Journal of General Internal Medicine, 2007, 22, 485-490.	1.3	113

#	Article	IF	CITATIONS
73	Racial and Socioeconomic Disparities in Bone Density Testing Before and After Hip Fracture. Journal of General Internal Medicine, 2007, 22, 1239-1245.	1.3	55
74	Bone Density Testing in Older Women and Its Association with Patient Age. Journal of the American Geriatrics Society, 2006, 54, 485-489.	1.3	34
75	The continuing evolution of women's health. Journal of General Internal Medicine, 2004, 19, 810-811.	1.3	1
76	Decentralization of breast cancer surgery in the United States. Cancer, 2004, 101, 1323-1329.	2.0	34
77	Diagnosis and Treatment of Osteoporosis in Patients with Vertebral Compression Fractures. Journal of the American Geriatrics Society, 2003, 51, 483-491.	1.3	38
78	Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density <subtitle>The Women's Health Initiative Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2003, 290, 1729.	3.8	1,006
79	Physician Counseling on Hormone Replacement Therapy and Bone Loss: Do Socioeconomic and Racial Characteristics of Women Influence Counseling?. Journal of Women's Health, 2003, 12, 495-504.	1.5	4
80	Diagnosis and Management of Adults with Pharyngitis: A Cost-Effectiveness Analysis. Annals of Internal Medicine, 2003, 139, 113.	2.0	88